| Literature DB >> 26074989 |
Hewei Qin1, Ping Liu1, Shengchao Lin2.
Abstract
Astragaloside IV (AsIV) is the major effective component extracted from the Chinese herbEntities:
Year: 2015 PMID: 26074989 PMCID: PMC4449906 DOI: 10.1155/2015/385154
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Comparison of blood lipid (mmol/L, ± s, n = 10).
| Group | TC | TAG | LDL-C | HDL-C |
|---|---|---|---|---|
| Control group | 4.16 ± 1.59 | 1.47 ± 0.18 | 1.11 ± 0.23 | 2.59 ± 0.12 |
| Model group | 16.12 ± 0.95∗ | 12.75 ± 2.65∗ | 6.48 ± 0.81∗ | 1.12 ± 0.13∗ |
| AMD3100 group | 16.10 ± 0.93 | 12.64 ± 2.25 | 6.28 ± 0.91 | 1.13 ± 0.13 |
| AsIV group | 10.96 ± 1.32△▲ | 4.78 ± 0.86△▲ | 4.30 ± 0.76△▲ | 2.90 ± 0.39△▲ |
Note: compared with control group: * P < 0.05; compared with model group: △ P < 0.05; compared with AMD3100 group: ▲ P < 0.05.
Comparison of LA, IMT, and PA ( ± s, n = 10).
| Group | LA (mm2) | IMT ( | PA (mm2) |
|---|---|---|---|
| Model group | 0.255 ± 0.007 | 0.159 ± 0.047 | 0.158 ± 0.016 |
| AMD3100 group | 0.447 ± 0.042△ | 0.074 ± 0.013△ | 0.076 ± 0.018△ |
| AsIV group | 0.532 ± 0.017△▲ | 0.028 ± 0.011△▲ | 0.012 ± 0.013△▲ |
Note: compared with model group: △ P < 0.05; compared with AMD3100 group: ▲ P < 0.05.
Comparison of FS, CA, and FCT ( ± s, n = 10).
| Group | FS (mm2) | CA (mm2) | FCT ( |
|---|---|---|---|
| Model group | 0.065 ± 0.002 | 0.093 ± 0.012 | 13.724 ± 0.443 |
| AMD3100 group | 0.031 ± 0.005△ | 0.041 ± 0.011△ | 4.136 ± 0.672△ |
| AsIV group | 0.002 ± 0.003△▲ | 0.013 ± 0.012△▲ | 2.306 ± 0.558△▲ |
Note: compared with model group: △ P < 0.05; compared with AMD3100 group: ▲ P < 0.05.
Comparison of PA/LA, CA/PA, and CA/FS ( ± s, n = 10).
| Group | PA/LA | CA/PA | CA/FS |
|---|---|---|---|
| Model group | 2.718 ± 0.386 | 0.581 ± 0.150 | 1.493 ± 0.290 |
| AMD3100 group | 0.690 ± 0.130△ | 0.776 ± 0.070△ | 2.516 ± 0.317△ |
| AsIV group | 0.041 ± 0.023△▲ | 0.797 ± 0.116△▲ | 3.546 ± 0.913△▲ |
Note: compared with model group: △ P < 0.05; compared with AMD3100 group: ▲ P < 0.05.
Figure 1Hematoxylin and eosin stained histological sections. Note: C: control group; M: model group; A: AMD3100 group; Z: AsIV group (magnification ×200).
Figure 2PAC-1, CD40L, and CXCR4 expression of platelet surface. Note: C: control group; M: model group; A: AMD3100 group; Z: AsIV group. Compared with control group: ∗ P < 0.05; compared with model group: △ P < 0.05; compared with AMD3100 group: ▲ P < 0.05.
Figure 3(a) The expression of SDF-1 and CXCR4 (optical density value). Compared with control group: ∗ P < 0.05; compared with model group: △ P < 0.05. (b) Expression of SDF-1 (magnification ×400). (c) Expression of CXCR4 (magnification ×400). Note: C: control group; M: model group; A: AMD3100 group; Z: AsIV group.
Figure 4(a) The expression of SDF-1, CXCR4 mRNA. (b, c) The expression of SDF-1, CXCR4 protein. Note: C: control group; M: model group; A: AMD3100 group; Z: AsIV group. Compared with control group: ∗ P < 0.05; compared with model group: △ P < 0.05.
Figure 5Identification of bone marrow-derived EPC (magnification ×200, VEGF-R positive cells, white shot; PE labeled VEGF-R antibodies stimulate green shoot).
Figure 6The expression CXCR4 on EPC. Note: C: control group; M: model group; A: AMD3100 group; Z: AsIV group. Compared with control group: ∗ P < 0.05; compared with model group: △ P < 0.05.